Your browser doesn't support javascript.
loading
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger, Caroline; Geroldinger, Angelika; Smeets, Dominiek; Braicu, Elena Ioana; Sehouli, Jalid; Koller, Julia; Wolf, Andrea; Darb-Esfahani, Silvia; Joehrens, Korinna; Vergote, Ignace; Vanderstichele, Adriaan; Boeckx, Bram; Lambrechts, Diether; Gabra, Hani; Wisman, G Bea A; Trillsch, Fabian; Heinze, Georg; Horvat, Reinhard; Polterauer, Stephan; Berns, Els; Theillet, Charles; Cacsire Castillo-Tong, Dan.
Afiliação
  • Kreuzinger C; Translational Gynecology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Geroldinger A; Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
  • Smeets D; KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.
  • Braicu EI; VIB, VIB Center for Cancer Biology, Laboratory for Translational Genetics, Leuven, Belgium.
  • Sehouli J; Tumor Bank Ovarian Cancer Network, Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Koller J; Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Wolf A; Tumor Bank Ovarian Cancer Network, Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Darb-Esfahani S; Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Joehrens K; Translational Gynecology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Vergote I; Translational Gynecology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Vanderstichele A; Tumor Bank Ovarian Cancer Network, Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Boeckx B; Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Lambrechts D; Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Gabra H; Department of Gynecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Wisman GBA; Department of Gynecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Trillsch F; KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.
  • Heinze G; VIB, VIB Center for Cancer Biology, Laboratory for Translational Genetics, Leuven, Belgium.
  • Horvat R; KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.
  • Polterauer S; VIB, VIB Center for Cancer Biology, Laboratory for Translational Genetics, Leuven, Belgium.
  • Berns E; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
  • Theillet C; Clinical Discovery Unit, Early Clinical Development, AstraZeneca, Cambridge, United Kingdom.
  • Cacsire Castillo-Tong D; Department of Gynecologic Oncology, Cancer Research Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Clin Cancer Res ; 23(24): 7621-7632, 2017 Dec 15.
Article em En | MEDLINE | ID: mdl-28972047
Purpose: Most high-grade serous ovarian cancer (HGSOC) patients develop recurrent disease after first-line treatment, frequently with fatal outcome. This work aims at studying the molecular biology of both primary and recurrent HGSOC.Experimental Design: Gene expression profiles of matched primary and recurrent fresh-frozen tumor tissues from 66 HGSOC patients were obtained by RNA sequencing. Clustering analyses and pairwise comparison of the profiles between matched samples and subsequent functional alignment were used for the identification of molecular characteristics of HGSOC.Results: Both primary and recurrent HGSOC samples presented predominant gene expression differences in their microenvironment, determined by a panel of genes covering all major pathways of immune activation together with a number of genes involved in the remodeling of extracellular matrix and adipose tissues. Stratifying tumor tissues into immune active and silent groups, we further discovered that although some recurrent tumors shared the same immune status as their primary counterparts, others switched the immune status, either from silent to active or active to silent. Interestingly, genes belonging to the B7-CD28 immune checkpoint family, known for their major role as negative regulators of the immune response, were overexpressed in the immune active tumors. Searching for potential tumor antigens, CEACAM21, a member of the carcinoembryonic antigen family, was found to be significantly overexpressed in immune active tissues in comparison with the silent ones.Conclusions: The results illustrate the complexity of the tumor microenvironment in HGSOC and reveal the molecular relationship between primary and recurrent tumors, which have multiple therapeutic implications. Clin Cancer Res; 23(24); 7621-32. ©2017 AACR.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso / Microambiente Tumoral / Antígenos de Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso / Microambiente Tumoral / Antígenos de Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Áustria